Market Place
Sourcing Support
Gyre Therapeutics Reports Q3 2024 Results & Business Update
13 Nov 2024 //
GLOBENEWSWIRE
Gyre Therapeutics Completes Pivotal Phase 3 Trial For CHB
22 Oct 2024 //
GLOBENEWSWIRE
Gyre Therapeutics to Present at H.C. Wainwright MASH Conference
01 Oct 2024 //
GLOBENEWSWIRE
Gyre Therapeutics To Present At H.C. Wainwright Conference
04 Sep 2024 //
GLOBENEWSWIRE
Gyre Therapeutics Reports Q2 2024 Results And Business Update
13 Aug 2024 //
GLOBENEWSWIRE
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
09 Aug 2024 //
GLOBENEWSWIRE
Gyre Therapeutics Appoints David Epstein To Board Of Directors
08 Aug 2024 //
GLOBENEWSWIRE
Gyre Therapeutics Announces NMPA Approval Of Avatrombopag Maleate Tablets
02 Jul 2024 //
GLOBENEWSWIRE
Gyre Announces Publication in Journal of Gastroenterology and Hepatology
18 Jun 2024 //
GLOBENEWSWIRE
Gyre Gets China IND Approval For F230 In Pulmonary Arterial Hypertension
30 May 2024 //
GLOBENEWSWIRE
Gyre Therapeutics: Expected Russell 2000, 3000 Index Additions
28 May 2024 //
GLOBENEWSWIRE
Gyre Therapeutics Q1 2024 Financials And Business Update
09 May 2024 //
GLOBENEWSWIRE
Gyre Therapeutics: Under The Radar Biotech Has A Shot At MASH Approval, In Time
13 Apr 2024 //
SEEKINGALPHA
Gyre Therapeutics Reports Full Year 2023 Financial Results
26 Mar 2024 //
GLOBENEWSWIRE
Gyre Therapeutics Expands Board of Directors with Appointment of Nussbaum
21 Mar 2024 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.